Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02527564 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT02527564: Completed Phase 4 study, sponsored by Stanford University.
NCT02527564 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02527564, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.
Interventions
- DRUG Placebo
- DRUG Suvorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02527564
The ClinicalTrials.gov registry entry for NCT02527564 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02527564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02527564 about?
NCT02527564 is a clinical study titled "Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder". The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improveme...
What is the current status of trial NCT02527564?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2015-09. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT02527564?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT02527564?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.